Case studies in autonomous scientific analysis
Each study addresses a real question a scientist or strategy team is trying to answer, and shows how Hydra plans, executes, and validates the analysis on public data. Illustrative, non-proprietary, and repointable to your own target.
- Molecule design
Why one ADC won
Same receptor, four drugs, one approval. Hydra worked out what separated the winner - from one prompt, in hours.
Read case study - Target discovery
Combinatorial therapy
Billions of gene pairs, no lab can test them all. We shortlist the handful worth running.
Read case study - Safety & translational
Safety signals in combinations
Two effective drugs can stack toxicities. We score which combinations actually stay safe.
Read case study - Competitive intelligence
Portfolio monitoring
Competitive landscapes go stale in weeks. We keep a live, subtype-level read you can re-run.
Read case study - Strategy & defensibility
Portfolio strategy
Costs keep rising while approvals don't. We turn your data into a compounding moat.
Read case study - Translational research
Augmenting in vivo studies
Over 90% of drugs fail, often too late. We read your in vivo results against the clinic to call it earlier.
Read case study - Interpretable AI
Novel targets & repurposing
DNA-repair-deficient gastric cancer with no BRCA mutation. A network found the driver statistics would bury - and an approved drug to hit it.
Read case study